SUPN — Supernus Pharmaceuticals, Inc. stock price, charts and financials
QT47Supernus Pharmaceuticals, Inc.Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.51 | Insider Own | 3.28% | Shs Outstand | 58.04M | Perf Week | 6.74% |
| Market Cap | 2.77B | Forward P/E | 10.23 | EPS next Y | 4.66 | Insider Trans | -9.52% | Shs Float | 54.44M | Perf Month | -2.28% |
| Enterprise Value | 2.63B | PEG | 0.24 | EPS next Q | - | Inst Own | - | Short Float | 8.91% | Perf Quarter | -8.88% |
| Income | -109.77M | P/S | 3.33 | EPS this Y | 649.02% | Inst Trans | - | Short Ratio | 6.31 | Perf Half Y | -3.50% |
| Sales | 830.43M | P/B | 2.68 | EPS next Y | 66.25% | ROA | -7.69% | Short Interest | 4.85M | Perf YTD | -4.14% |
| Book/sh | - | P/C | 138.94 | EPS next 5Y | 19.97% | ROE | -10.42% | 52W High | 59.30 -20.17% | Perf Year | 12.25% |
| Cash/sh | - | P/FCF | 147.18 | EPS past 3/5Y | - | ROIC | -9.12% | 52W Low | 40.01 18.33% | Perf 3Y | 51.09% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 2.53% 6.70% | Gross Margin | 88.07% | Volatility | 9.16% 4.57% | Perf 5Y | 80.93% |
| Dividend TTM | - | EV/Sales | 3.16 | EPS Y/Y TTM | -138.64% | Oper. Margin | -13.46% | ATR (14) | 2.29 | Perf 10Y | 111.45% |
| Dividend Ex-Date | - | Quick Ratio | 1.84 | Sales Y/Y TTM | 17.37% | Profit Margin | -13.23% | RSI (14) | 53.56 | Recom | 2.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.08 | EPS Q/Q | 40.48% | SMA20 | 1.83% | Beta | 0.57 | Target Price | 65.00 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | 38.67% | SMA50 | 3.17% | Rel Volume | 0.81 | Prev Close | 47.64 |
| Employees | 778 | LT Debt/Eq | 0.03 | Earnings | Nov 03 | SMA200 | -2.62% | Avg Volume | 855.24K | Price | 47.34 |
| IPO Date | May 01, 2012 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 98.32% 7.67% | Net Debt/EBITDA | 8.81 | Volume | 695,164 | Change | -0.63% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-25-26 | Reiterated | Craig-Hallum | $65 | |
| Dec-19-25 | Reiterated | Stifel Nicolaus | Hold | $50 → $55 |
| Oct-09-25 | Upgrade | Piper Sandler | Neutral → Overweight | $65 |
| Sep-30-25 | Reiterated | Cantor Fitzgerald | Overweight | $42 → $63 |
| Aug-29-25 | Reiterated | Piper Sandler | Neutral | $36 → $40 |
| Jul-29-25 | Reiterated | Cantor Fitzgerald | Neutral | $42 |
| Feb-19-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral | |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral | $41 → $36 |
| May-24-24 | Reiterated | Piper Sandler | Overweight | $41 |
| Apr-08-24 | Reiterated | Jefferies | Buy | $40 |
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 831 | 719 | 662 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 99 | 75 | 78 | — | — | — | — | — | — | |
| Gross Profit | 731 | 644 | 584 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 561 | 486 | 336 | — | — | — | — | — | — | |
| Research and Development | 125 | 106 | 109 | — | — | — | — | — | — | |
| Other Operating Expense | 158 | 89 | 57 | — | — | — | — | — | — | |
| Operating Income | -111 | -37 | 82 | — | — | — | — | — | — | |
| Interest Expense | 2 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -10 | -12 | 16 | — | — | — | — | — | — | |
| Net Income Before Taxes | -124 | -49 | 98 | — | — | — | — | — | — | |
| Income Taxes | -14 | -10 | 24 | — | — | — | — | — | — | |
| Consolidated Net Income | -109 | -39 | 74 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -109 | -39 | 74 | — | — | — | — | — | — | |
| Net Income | -109 | -39 | 74 | — | — | — | — | — | — | |
| EPS (Recurring) | -1.92 | -0.68 | 1.34 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.92 | -0.68 | 1.34 | — | — | — | — | — | — | |
| EPS (Diluted) | -1.92 | -0.68 | 1.32 | — | — | — | — | — | — | |
| EBITDA | -16 | 43 | 178 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 27.39 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.30 | 3.87 | 3.00 | — | — | — | — | — | — | |
| Gross Margin | 87.97 | 89.57 | 88.22 | — | — | — | — | — | — | |
| Operating Margin | -13.36 | -5.15 | 12.39 | — | — | — | — | — | — | |
| Net Margin | -13.12 | -5.42 | 11.18 | — | — | — | — | — | — | |
| Shares Outstanding | 58 | 56 | 55 | — | — | — | — | — | — | |
| Market Capitalization | 2,746 | 2,783 | 1,989 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 18 '26 | Sale | 49.60 | 7,250 | 359,621 | 17,044 | Mar 18 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 18 '26 | Option Exercise | 39.40 | 7,250 | 285,650 | 24,294 | Mar 18 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 17 '26 | Sale | 50.30 | 50,000 | 2,514,887 | 17,044 | Mar 18 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 17 '26 | Option Exercise | 38.51 | 50,000 | 1,925,538 | 67,044 | Mar 18 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 16 '26 | Sale | 50.28 | 50,000 | 2,513,925 | 17,044 | Mar 18 |
| Bhatt Padmanabh P. | Sr. VP of IP, CSO | Mar 16 '26 | Option Exercise | 33.62 | 50,000 | 1,681,206 | 67,044 | Mar 18 |
| Khattar Jack A. | President, CEO | Mar 13 '26 | Sale | 50.38 | 35,000 | 1,763,124 | 958,100 | Mar 16 |
| Hudson Frederick M. | Director | Mar 12 '26 | Sale | 50.61 | 5,369 | 271,725 | 60,413 | Mar 16 |
| Horich William Todd | SVP, Commercial Operations | Mar 10 '26 | Sale | 55.00 | 4,439 | 244,145 | 0 | Mar 10 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer | Mar 09 '26 | Sale | 53.65 | 1,623 | 87,074 | 18,440 | Mar 10 |
| Horich William Todd | SVP, Commercial Operations | Mar 09 '26 | Sale | 54.00 | 4,438 | 239,652 | 4,439 | Mar 10 |
| Khattar Jack A. | President, CEO | Mar 06 '26 | Option Exercise | 0.00 | 38,640 | 0 | 1,245,218 | Mar 10 |
| Mottola Frank | SVP, Chief Tech. Ops. Officer | Mar 06 '26 | Option Exercise | 0.00 | 3,750 | 0 | 21,856 | Mar 10 |
| DEC TIMOTHY C | Senior Vice-President & CFO | Mar 06 '26 | Option Exercise | 0.00 | 6,000 | 0 | 9,682 | Mar 10 |
| Horich William Todd | SVP, Commercial Operations | Mar 06 '26 | Option Exercise | 0.00 | 7,500 | 0 | 9,991 | Mar 10 |